Optimizing treatment for HER2-positive HR-positive breast cancer

During the last three decades, the human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treatment landscape has changed dramatically [1]. Various anti-HER2 drugs and chemotherapy combinations have been explored in large prospective phase III trials, either in early or advanced settings. HER2 blockade has been maximized with the indication for dual anti-HER2 blockade in early and metastatic HER2-positive BC [2,3]. However, it has also become apparent that HER2-positive BC is a complex disease in view of the heterogeneity of HER2 expression and hormone receptor (HR) expression and their impact on the natural history of the disease [4].

Source: Cancer Treatment Reviews - February 28, 2023 Category: Cancer & Oncology Authors: Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart Tags: Anti-tumour Treatment Source Type: research